RIPK1 and neoplasm: The authors showed that in acute DSS-induced colitis, treatment of mice with the RIPK1 inhibitor necrostatin-1 triggered anti-inflammatory and antitumorigenic effects that attenuated intestinal inflammation and colitis-associated tumor growth in mice [37].